Treatment
We adopted an original, full-dose FOLFIRINOX regimen because at the time of study planning there was little evidence which supported modified regimen such as an omission of bolus-fluorouracil could ensure an improved safety without compromising efficacy of the treatment. Thus, patients initially received oxaliplatin 85 mg/m